A new consultation seeks PCR automation, high-throughput sequencing and digital PCR, signalling wider public demand for integrated molecular biology workflows.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
Resah has opened a wide‑ranging consultation on molecular biology and next‑generation sequencing (NGS) technologies, spanning PCR automation, nucleic acid extraction, high‑throughput sequencing, library preparation and digital PCR. The plans point to a public buyer looking to assemble a comprehensive suite of tools for advanced laboratory analysis.
In December 2025, Resah published a contract notice for a consultation titled Molecular Biology and NGS Solutions. According to the notice, the consultation seeks to provide a range of molecular biology and NGS sequencing solutions across multiple technology types.
The buyer highlights needs in:
This mix reaches from automated PCR workflows and sample preparation through to high‑throughput sequencing and digital PCR, rather than concentrating on a single instrument. The notice presents the exercise as a consultation rather than a fixed order.
The Resah consultation sits within a wider set of public‑sector procurements that are expanding molecular biology and sequencing capabilities in hospitals and specialist centres. Many of these notices tie new equipment and kits directly to particular clinical services.
In July 2025, oncology providers highlighted how central sequencing has become to cancer care. The Emergency County Clinical Hospital “Saint Apostle Andrew” in Constanta published the Supply and Installation of Genetic Equipment notice, aiming to enhance diagnostic capabilities and oncological treatment accessibility with advanced genetic medical equipment. That same month, Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli launched Next-Generation Sequencing System Delivery to equip its Clinical Genetics Center with an NGS system and associated devices for specialised diagnostics and treatment of oncological patients.
Later in October 2025, ASST Spedali Civili di Brescia opened a tender for the Supply of NGS Systems and Reagents, covering NGS analytical systems, sequencers, reagents and bioinformatics software for genomic profiling and molecular characterisation in oncology and hereditary diseases. In December 2025, Hospital Universitario Fundación Alcorcón focused on biomarkers through its Supply of NGS Reagents notice, seeking materials for detecting actionable biomarkers in cancer.
Across these oncology‑focused tenders, public buyers are explicitly linking investment in NGS systems, reagents and bioinformatics to improved cancer diagnostics and access to advanced treatments.
Automation and throughput are another recurring theme. Also in July 2025, Land Baden‑Württemberg’s State Health Office issued an Automated System for PCR Testing contract notice, seeking a fully automated real‑time PCR platform for HIV/AIDS and STI diagnostics capable of processing more than 250 samples in eight hours, backed by a monthly supply of reagents. In September 2025, Healthcare Public Procurement (HeCaPP) combined a molecular biology automation system with maintenance services and HPV screening kits in its Molecular Biology Automation System procurement.
At the same time, oncology centre Centrum Onkologii im. Franciszka Łukaszczyka w Bydgoszczy sought broader genetic diagnostics capacity through its September 2025 Genetic Diagnostics Equipment Delivery tender, bundling next‑generation sequencers with different throughputs and a pipetting station, plus assembly, installation, commissioning and training. Against this backdrop, Resah’s consultation, with its emphasis on PCR automation, extraction tools and high‑throughput sequencing options, aligns closely with a broader shift towards automated, high‑capacity molecular testing environments.
A series of other procurements show public buyers concentrating on reagents, bioinformatics and analytical support rather than solely on instruments. In August 2025, Centre Hospitalier Universitaire de Clermont‑Ferrand published NGS Sequencing Reagents and Services to secure reagents and associated bioinformatics services for a range of genetic analyses. In July 2025, VšĮ Vilniaus universiteto ligoninė Santaros klinikos launched Reagents and Bioinformatics for Sequencing, covering reagents, disposable materials and bioinformatics analysis for cytogenomics, epigenomics and NGS, including DNA and RNA library preparation kits and sequencing management.
Some tenders are tailored to specific genetic applications but still pair consumables with interpretation tools. The October 2025 notice from Etablissement français du sang, HLA Typing Reagents for NGS, combines reagents, interpretation software and related materials for high‑resolution HLA typing using Miseq and Nanopore platforms. The Macedonian Academy of Sciences and Arts, in its November 2025 Oncology Sequencing Kits and Reagents contract notice, seeks kits and reagents for oncology and cancer gene panels, including single‑cell kits, polymerases, buffer containers and specialised oligonucleotides.
Elsewhere, buyers are choosing to purchase sequencing as a service. INRAE’s September 2025 Genomic Sequencing Services consultation seeks high‑throughput DNA and RNA sequencing services to analyse genomes, methylation and gene expression, along with secure delivery of sequencing data. In December 2025, Rīgas Stradiņa universitāte published NGS Outsourcing Services to cover various NGS applications, from sequencing of prepared libraries to library preparation with sequencing and a range of specialised techniques.
These service‑ and consumable‑oriented procurements complement the equipment‑focused hospital tenders, suggesting that public buyers increasingly view sequencing as an ecosystem. Instruments, reagents, bioinformatics and external services are being procured as interdependent components rather than in isolation.
Resah is not alone in using consultations to shape its approach. Region Uppsala’s December 2025 RFI for Sequencing Equipment seeks information from suppliers on an IVDR‑certified sequencing solution, including instruments and support, to enhance genetic and pathological diagnostics for various patient groups. In November 2025, Radboud Universitair Medisch Centrum issued a Market Consultation for Molecular Diagnostics, looking for equivalent DNA extraction and real‑time PCR solutions that can replace existing systems while staying compatible with current workflows and accreditation standards.
Centre Hospitalier Universitaire de Liège has also taken a staged approach. Its August 2025 prior information notice, Acquisition of NGS Preparation Instruments, sets out plans to obtain a Genexus instrument and associated reagents for NGS library preparation and sequencing, with the twin goals of enhancing laboratory capabilities and reducing turnaround times for patient results.
Viewed alongside these prior information notices and RFIs, Resah’s Molecular Biology and NGS Solutions consultation reinforces a trend towards engaging the market early. Rather than moving straight to detailed specifications, a number of buyers are first testing how best to combine instruments, reagents, software and support within coherent sequencing solutions.
The current wave of notices shows public‑sector organisations investing across the full spectrum of molecular biology and NGS activity: automation, high‑throughput sequencers, disease‑specific assays, reagents, bioinformatics and outsourced services. Resah’s consultation, with its explicit focus on PCR automation systems, nucleic acid extraction tools, high‑throughput sequencing options, library preparation kits and digital PCR solutions, captures many of these strands in a single exercise.
The outcome of the consultation is not yet defined in the notice, but any follow‑up procurements will indicate how far buyers choose tightly integrated machine‑and‑reagent systems or more modular combinations of platforms and services. Alongside other consultations from Region Uppsala, Radboudumc and CHU Liège, the Resah process will be one to watch for signals on how public laboratories intend to organise their next generation of molecular testing.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.